Practice for implementation and authorisation of name changes

Updated 26 January 2018

A new practice related to the authorisation and implementation of changes to the marketing authorisation holder (MAH) and consequential changes to the name of the medicine consisting of the generic name and the MAH's company name or brand entered into force on 1 November 2004.

The Danish Medicines Agency will in future require that the name of the medicine and the marketing authorisation holder (MAH) be changed at the same time when the authorised medicinal product name consists of the generic name and the company name or brand.

Under the previous practice, it was accepted that when the MAH changed, the generic name which included the previous MAH remained unchanged for a transitional period.

The changed practice means that the summary of product characteristics and Medicine Prices will not be updated with the new authorised MAH and the belonging generic name until the MAH has notified the Danish Medicines Agency (Pharmacoeconomic Division) that the existing generic name will no longer be marketed. Please be aware that the packages must bear a new product number.

Generally, the above provision cannot be waived.

Reference is made to the Danish Medicines Agency's guideline on variations to marketing authorisations for medicinal products

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.